The anthracycline antitumor agents doxorubicin and daunorubicin reduce the activity of Candida albicans phospholipase B.
A pathogenic yeast, Candida albicans, causes life-threatening infection in immunocompromised patients. Inhibiting the production or release of phospholipase B by C. albicans should reduce direct host cell damage, and inhibit the release of eicosanoids from cells of this microorganism. Of the antitumor agents tested, doxorubicin and daunorubicin inhibited the activity of phospholipase B, and prostaglandin production by C. albicans. These two agents have the potential to inhibit the activity of C. albicans phospholipase B, although the inhibitory concentrations exceeded the clinical dose.
Arai
Rika
R
Department of Microbiology, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan.
Sugita
Takashi
T
Nishikawa
Akemi
A
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects* / Q000201:enzymology; D003630:Daunorubicin / Q000494:pharmacology*; D004317:Doxorubicin / Q000494:pharmacology*; D006801:Humans; D008245:Lysophospholipase / Q000187:drug effects*; D008826:Microbial Sensitivity Tests
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; D008245:Lysophospholipase; D003630:Daunorubicin